Amyloid cardiomyopathy
- 27 February 2020
- journal article
- research article
- Published by Springer Nature in Herz
- Vol. 45 (3) , 267-271
Abstract
Cardiac amyloidosis is a heterogeneous group of diseases characterized by extracellular deposition of amyloid fibrils in many different organs finally resulting in organ failure. Cardiac involvement is common for immunoglobulin light chain amyloidosis (AL) or transthyretin amyloidosis (ATTR); the latter is caused by a transthyretin gene variant or wild-type protein. Precise diagnostic assessment including laboratory tests, electrocardiography, echocardiography, cardiac magnetic resonance imaging, biopsy, and/or bone scintigraphy is mandatory for definition of the amyloid type and finally for treatment initiation. Treatment of cardiac amyloidosis includes symptomatic therapy of heart failure as well as the underlying disease. Causative treatment of AL amyloidosis is according to regimens used for multiple myeloma. For many years, orthotopic liver transplantation was the only treatment available for hereditary ATTR amyloidosis, but important advances have been made after approval of a novel class of medication, namely, RNA silencers. However, currently no treatment is available to remove amyloid deposited in the tissue. Thus, early diagnosis is still critical to afford the best efficacy of available therapies.Keywords
This publication has 25 references indexed in Scilit:
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac AmyloidosisCirculation: Heart Failure, 2019
- Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanzaRevista Espanola de Cardiologia, 2017
- Genotype and Phenotype of Transthyretin Cardiac AmyloidosisJACC, 2016
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCirculation, 2016
- Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisJACC, 2015
- Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesAmerican Journal of Hematology, 2015
- Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variantEuropean Heart Journal, 2011
- Systemic Cardiac AmyloidosesCirculation, 2009
- Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2‐macroglobulinandtau: A population‐based autopsy studyAnnals of Medicine, 2008
- The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvementQJM: An International Journal of Medicine, 1998